Clinical Trials Logo

Clinical Trial Summary

Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying patterns of tumor spread. The optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which are most effective include doxorubicin and ifosfamide, but objective response rates and progression-free survival times remain modest. There is clearly a need to improve treatment options for liposarcoma. Eribulin, a antimicrotubule agent that targets the protein tubulin in cells, interfering with cancer cell division and growth , has demonstrated activity in STS. Therefore, it is reasonable to explore whether other anti-microtubule agent like cabazitaxel have a role in STS. Cabazitaxel has been shown to be a relatively safe, effective and tolerated. This drug has been approved by FDA for prostate cancer. The main objective of this trial is to determine whether cabazitaxel demonstrate sufficient antitumor activity for liposarcoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01913652
Study type Interventional
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact
Status Completed
Phase Phase 2
Start date October 2014
Completion date December 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03307616 - Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery Phase 2
Not yet recruiting NCT06389799 - A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Phase 2
Recruiting NCT05886634 - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Phase 2
Completed NCT06115681 - Real-world Study of Dedifferentiated Liposarcoma Patients in China
Active, not recruiting NCT02846987 - Study of Abemaciclib in Dedifferentiated Liposarcoma Phase 2
Terminated NCT04979442 - Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma Phase 3
Completed NCT02606461 - Selinexor in Advanced Liposarcoma Phase 2/Phase 3
Active, not recruiting NCT04242238 - Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Phase 1
Withdrawn NCT00969917 - Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Phase 2
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Terminated NCT03604783 - Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05496569 - TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma Phase 2